Immuno-oncology biotech Immune Design sets terms for $60 million IPO

By
A A A

Immune Design, an early-stage biotech developing immunotherapy oncology treatments, announced terms for its IPO on Monday. The Seattle, WA-based company plans to raise $60 million by offering 4.7 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Immune Design would command a fully diluted market value of $221 million.

Immune Design, which was founded in 2008 and booked $1 million in licensing and product sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol IMDZ. Immune Design initially filed confidentially on April 24, 2014. Jefferies and Leerink Partners are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: IMDZ

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

89,070,840
  • $17.26 ▲ 3.23%
78,931,485
  • $7.02 ▲ 4.46%
77,555,734
  • $6.70 ▲ 6.69%
77,025,346
  • $24.66 ▲ 0.69%
74,713,335
  • $101.80 ▲ 1.82%
72,324,726
  • $7.64 ▲ 0.79%
57,112,188
  • $17.84 ▲ 55.27%
53,321,397
  • $18.01 ▼ 4.46%
As of 12/17/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com